Ipilimumab

Drug #2270

Ipilumumab is a T-cell potentiator, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) is a negative regulator of T-cell activation leading to tumor cell death. Ipilimumab is a monoclonal antibody (IgG1k) of fully human use which is indicated in the treatment of advanced (unrescectable or metastatic) melanoma in adults who have recieved prior therapy.

← Previous drug Next drug →

Primary Characteristics

It belongs to T-cell activator or potentiator pharmacological group on the basis of mechanism of action.

Molecular Weight: 148634.91 · Non-proprietary name: Ipilimumab · pH: 7.

Pharmacokinetics

Distribution: Ipilimumab has a volume of distribution is 7.22 L.

Elimination: plasma half-life is 15 days, renal excretion is Systemic clearence 15.3ml/hr (38.5%).

Indications

Ipilimumab is primarily indicated in conditions like advanced melanoma.

Contraindications

Ipilimumab is contraindicated in conditions like Hypersensitivity.

Dosage

Ipilimumab's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
3 mg/kg	3 mg/kg	—	IV	Administer IV over 90 minute period. patient should recieve entire regimen in dilution (4 doses) as tolerated. assessment of tumor response should be conducted only after therapy. LFT & TFT should be evaluated at baseline before each dose of ipilimumab. must not be administer as an IV push or bolus. can be given as a dilution of NaCl 9mg/ml (0.9%) solution for injection or glucose 50mg/ml (5%) solution for injection to concentration between 1 & 4 mg/ml.
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

2 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Ipilimumab in overdosage may give rise to further complications which include Hepatotoxicity , Abdominal pain, Elevated SGPT & SGOT, Hepatotoxicity , Enterocolitis, Aseptic meningitis, Hypophysitis.

Ipilimumab produces potentially life-threatening effects which include Adrenal Insufficiency , Stevens Johnson syndrome, Severe diarrhea, Stevens Johnson syndrome, Adrenal insufficiency, Toxic epidermal necrolysis, GI hemorrhage, skin rash, GI perforation, hypopituitarism, hyperthyroidism, hypothyroidism. Careful monitoring is needed with proper medical management.

Ipilimumab is known to cause more or less tolerable side effects which are usually transient. These include Abdominal pain, amylase elevation, Colitis, Decreased appetite, Dermatitis, Diarrhea, esinophilia, Fatigue, glomerulonephritis, Hemolytic anemia, Hepatitis, Iritis, lipase elevation, Nausea, oxygen failure, Pancreatitis, Pneumonitis, Pruritus , Rashes , Uveitis, Vomiting .

Warnings / Precautions

It can result in immune related adverse reactions which can be life threatening involving GI, liver, skin, nervous, endocrine and other organ system. ipilimumab is associated with inflammatory adverse reactions resulting from increase or exercise immune activity which can be severe. severe immune reactions can also occur. severe infusion reaction may occur as well. It should be avoided in patients with severe active immune disease. use with caution in patients who are on controlled sodium diet. Patient should be advised to take caution when driving or operating machinery.

Available Brands

None recorded.

Storage Conditions

Ipilimumab should be stored injection.